The drug delayed patients’ worsening by about five months over the course of the study, Japanese drugmaker Eisai’s Dr. Michael Irizarry said.Read More
The drug delayed patients’ worsening by about five months over the course of the study, Japanese drugmaker Eisai’s Dr. Michael Irizarry said.Read More